Jules G Becher Selected Research

Rhizotomy

1/2018	Erratum: Risk Factors for Dystonia after Selective Dorsal Rhizotomy in Nonwalking Children and Adolescents with Bilateral Spasticity.
1/2018	Risk Factors for Dystonia after Selective Dorsal Rhizotomy in Nonwalking Children and Adolescents with Bilateral Spasticity.
5/2015	Long-term outcome in selective dorsal rhizotomy in spastic cerebral palsy: differentiation in mobility levels is needed.
4/2014	Selection criteria for selective dorsal rhizotomy in children with spastic cerebral palsy: a systematic review of the literature.
7/2013	Long-term effect of selective dorsal rhizotomy on gross motor function in ambulant children with spastic bilateral cerebral palsy, compared with reference centiles.
6/2011	Long-term outcome and adverse effects of selective dorsal rhizotomy in children with cerebral palsy: a systematic review.
5/2011	Short- and long-term effects of selective dorsal rhizotomy on gross motor function in ambulatory children with spastic diplegia.
2/2010	Preoperative MRI findings and functional outcome after selective dorsal rhizotomy in children with bilateral spasticity.
5/2009	Disappearance of spasticity after selective dorsal rhizotomy does not prevent muscle shortening in children with cerebral palsy: a case report.
7/2008	Effectiveness of selective dorsal rhizotomy in 2 patients with progressive spasticity due to neurodegenerative disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jules G Becher Research Topics

Disease

34	Cerebral Palsy (Spastic Diplegia) 01/2023 - 05/2005
7	Dystonia (Limb Dystonia) 01/2023 - 11/2011
5	Muscle Spasticity (Spastic) 12/2016 - 05/2009
2	Pain (Aches) 01/2023 - 11/2011
1	Metachromatic Leukodystrophy (Sulfatide Lipidosis) 01/2019
1	Muscular Diseases (Myopathy) 09/2010
1	Paresis (Hemiparesis) 02/2010
1	Movement Disorders (Movement Disorder) 01/2010
1	Dyskinesias (Dyskinesia) 10/2008
1	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2008
1	Disease Progression 07/2008

Drug/Important Bio-Agent (IBA)

7	Baclofen FDA LinkGeneric 01/2023 - 05/2009
6	Type A Botulinum Toxins (Botox)FDA Link 12/2016 - 05/2005
2	Botulinum Toxins (Botulinum Toxin)IBA 12/2016 - 01/2010
1	benzoylamido- 4'- aminostilbene- 2,2'- disulfonate (BADS)IBA 01/2020
1	incobotulinumtoxinA FDA Link 12/2016
1	Magnesium Sulfate (Sulfate, Magnesium)FDA LinkGeneric 01/2016
1	Oxygen (Dioxygen)IBA 01/2014
1	CP 14IBA 01/2010

Therapy/Procedure

11	Rhizotomy 01/2018 - 06/2005
7	Foot Orthoses 02/2018 - 09/2010
5	Resistance Training 10/2018 - 10/2008
4	Therapeutics 01/2019 - 05/2009
2	Injections 06/2008 - 05/2006
1	Aftercare (After-Treatment) 01/2020
1	Activities of Daily Living (ADL) 10/2018
1	Orthotic Devices (Orthosis) 02/2013
1	Splints (Splint) 03/2012